Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

ID
Name
NAP03
Description
This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients
Trial arms
Trial start
2021-07-01
Estimated PCD
2021-09-30
Trial end
2021-09-30
Status
Completed
Phase
Early phase I
Treatment
Calcitriol
The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
Arms:
Calcitriol
Other names:
Oscal
Placebo
Placebo give 2x1 per day for five day
Arms:
Control
Size
16
Primary endpoint
HsCRP
Hs CRP (high sensitive c reactive protein) examination was carried out on the first day of hospitalization and the 5th day of hospitalization
Eligibility criteria
Inclusion Criteria: * COVID-19 patients, hospitalized patients, and patients aged 18-60 years Exclusion Criteria: * pregnancy
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'This study used calcitriol and a placebo, which were similar in shape; researchers and patients did not know who was getting the drug or placebo.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 16, 'type': 'ACTUAL'}}
Updated at
2023-03-13

1 organization

1 product

1 indication

Organization
Universitas Sebelas Maret
Product
Calcitriol
Indication
COVID-19